{'fraction_non_alphanumeric': 0.021404109589041095, 'fraction_numerical': 0.00684931506849315, 'mean_word_length': 6.590909090909091, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Retroperitoneoscopic Resection of Paraganglioma in a Hemodialysis Patient.

Background: Paraganglioma is rarely reported in patients on hemodialysis. We present a hemodialysis patient in whom incidentally identified paraganglioma was treated by retroperitoneoscopic resection. Case Presentation: A retroperitoneal tumor was identified incidentally in an 80-year-old man on hemodialysis for chronic renal dysfunction. The patient did not complain of any clinical symptoms suggestive of paraganglioma and plasma catecholamines levels were normal. However, iodine-123-metaiodobenzylguanidine (123I-MIBG) scintigraphy showed obvious radionuclide accumulation in the tumor, leading to a diagnosis of paraganglioma. After initiation of treatment with an alpha-adrenergic receptor blocker, retroperitoneoscopic resection of the tumor was performed. Pathological examination confirmed the diagnosis of pheochromocytoma. Conclusion: Although testing urine samples is unlikely available in hemodialysis patients, paraganglioma can be diagnosed by MIBG scintigraphy. Retroperitoneoscopic resection is effective for managing retroperitoneal paraganglioma in hemodialysis patients.